Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Envista Holdings (NVST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$27.19+9.77%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.67 → 1.66 EPS · FY ending Dec 31, 2027 · 9 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 9; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NVST yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA growth to at least $99 million | Profit margins improve with adjusted EBITDA rising 25% year-on-year. | Intact | Adjusted EBITDA falls below $79 million next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is an execution-led healthcare growth story, not a proven durable compounder, because the company remains loss-making. The long-term thesis is intact, with recent results holding in the upper half of the industry and management delivering on operating improvements.
The valuation evidence is mixed: NVST is described as cheap versus peers, yet it also carries a sizable peer premium and the overall value assessment is expensive. Expectations appear justified, with low fragility signals and no major warning gates, but the company still needs to support its growth and operating progress.
Near term, recent results and execution have been strong: operating income, margins, and free cash flow rose between 2025-Q4 and 2026-Q2, and management raised its 2026 core sales growth outlook. The growth picture is mixed because quarterly revenue was lower than in 2025-Q4, and a guidance cut or weaker jobs data could pressure results; the company also has a history of a deep miss.
Over the next few quarters, the thesis hinges on maintaining the raised growth outlook and continuing operating improvements while sustaining free cash flow conversion. A guidance cut or further labor-market weakening would be unfavorable, while continued strength from healthcare peers could support the sector backdrop.
For the next 1 to 3 years, NVST’s thesis rests on turning recent operational progress into steadier growth, with valuation expectations and the risk of weaker guidance as key checks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Envista grows core sales about 9.5% yearly. |
| Broken |
| YoY revenue growth falls below 4% next year |
Revenue growth: 3.22% FY2026-Q3; GAAP. Published target: >=9.5% YoY. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Nov 4, 20263.224362 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Free cash flow near positive conversion with ~$100% conversion rate | Free cash flow guidance is maintained despite short-term volatility. | Improving | Free cash flow remains negative beyond Q1 2026 | Free cash flow: $88.5M FY2026-Q2; GAAP. Published target: sustain ~100% free cash flow conversion. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 202688,500,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain share repurchases at or above recent levels | A supporting condition in Envista Holdings's published investment case. The stated target is >=1.6 million shares repurchased per quarter. | Intact | Share repurchases drop below 1 million shares per quarter | Required source inputs unavailable Cannot calculate Share repurchases from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.57 → $1.66 · observed estimates
$2.96B → $2.98B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.57 | $2,959,215,798 | 10 / 11 |
| 2026-07-25 | $1.57 | $2,959,576,450 | 16 / 15 |
| 2026-07-26 | $1.57 | $2,959,576,450 | 16 / 15 |
| 2026-07-27 | $1.57 | $2,959,215,798 | 10 / 12 |
| 2026-07-28 | $1.57 | $2,959,576,450 | 16 / 15 |
| 2026-07-29 | $1.57 | $2,956,916,870 | 16 / 15 |
| 2026-07-30 | $1.57 | $2,956,916,870 | 16 / 15 |
| 2026-07-31 | $1.57 | $2,956,916,870 | 16 / 15 |
| 2026-08-01 | $1.57 | $2,956,556,763 | 10 / 12 |
| 2026-08-02 | $1.57 | $2,956,916,870 | 16 / 15 |
| 2026-08-03 | $1.57 | $2,956,916,870 | 16 / 15 |
| 2026-08-04 | $1.57 | $2,956,556,763 | 10 / 12 |
| 2026-08-05 | $1.57 | $2,956,556,763 | 10 / 12 |
| 2026-08-06 | $1.57 | $2,956,556,763 | 10 / 12 |
| 2026-08-07 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-08 | $1.64 | $2,976,234,260 | 16 / 14 |
| 2026-08-09 | $1.64 | $2,976,234,260 | 16 / 14 |
| 2026-08-10 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-12 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-13 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-14 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-15 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-16 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-17 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-18 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-19 | $1.65 | $2,974,925,255 | 10 / 12 |
| 2026-08-20 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-21 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-22 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-23 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-24 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-25 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-26 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-27 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-28 | $1.67 | $2,983,038,409 | 10 / 12 |
| 2026-08-29 | $1.67 | $2,983,040,282 | 10 / 12 |
| 2026-08-30 | $1.67 | $2,983,040,282 | 10 / 12 |
| 2026-08-31 | $1.67 | $2,983,040,282 | 10 / 12 |
| 2026-09-01 | $1.67 | $2,983,040,282 | 10 / 12 |
| 2026-09-02 | $1.67 | $2,983,000,282 | 10 / 12 |
| 2026-09-03 | $1.67 | $2,983,000,282 | 10 / 12 |
| 2026-09-04 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-05 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-06 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-07 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-08 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-09 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-10 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-11 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-12 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-13 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-14 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-15 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-16 | $1.67 | $2,983,465,075 | 10 / 12 |
| 2026-09-17 | $1.67 | $2,983,466,949 | 10 / 12 |
| 2026-09-18 | $1.67 | $2,983,466,949 | 10 / 12 |
| 2026-09-19 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-20 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-21 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-22 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-23 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-24 | $1.67 | $2,981,772,062 | 10 / 12 |
| 2026-09-25 | $1.67 | $2,984,772,062 | 10 / 12 |
| 2026-09-26 | $1.67 | $2,984,938,409 | 10 / 12 |
| 2026-09-27 | $1.67 | $2,985,138,409 | 10 / 11 |
| 2026-09-28 | $1.67 | $2,985,138,409 | 10 / 11 |
| 2026-09-29 | $1.67 | $2,985,138,409 | 10 / 11 |
| 2026-09-30 | $1.67 | $2,985,102,417 | 9 / 11 |
| 2026-10-01 | $1.67 | $2,985,102,417 | 9 / 11 |
| 2026-10-02 | $1.67 | $2,985,102,417 | 9 / 11 |
| 2026-10-03 | $1.67 | $2,983,273,846 | 9 / 11 |
| 2026-10-04 | $1.67 | $2,983,273,846 | 9 / 11 |
| 2026-10-05 | $1.67 | $2,983,273,846 | 9 / 11 |
| 2026-10-06 | $1.67 | $2,981,559,560 | 9 / 11 |
| 2026-10-07 | $1.67 | $2,981,559,560 | 9 / 11 |
| 2026-10-08 | $1.66 | $2,980,716,218 | 9 / 11 |
| 2026-10-09 | $1.66 | $2,980,716,218 | 9 / 11 |
| 2026-10-10 | $1.66 | $2,980,437,647 | 9 / 11 |
| 2026-10-11 | $1.66 | $2,980,437,647 | 9 / 11 |
| 2026-10-12 | $1.66 | $2,980,437,647 | 9 / 11 |
| 2026-10-13 | $1.66 | $2,980,436,925 | 9 / 11 |
| 2026-10-14 | $1.66 | $2,980,436,925 | 9 / 11 |
| 2026-10-15 | $1.66 | $2,980,436,925 | 9 / 11 |
| 2026-10-16 | $1.66 | $2,979,422,640 | 9 / 11 |
| 2026-10-17 | $1.66 | $2,979,422,640 | 9 / 11 |
| 2026-10-18 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-19 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-20 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-21 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-22 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-23 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-24 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-25 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-26 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-27 | $1.66 | $2,979,422,640 | 9 / 10 |
| 2026-10-28 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-10-29 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-10-30 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-10-31 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-11-01 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-11-02 | $1.66 | $2,981,517,065 | 9 / 10 |
| 2026-11-03 | $1.66 | $2,981,502,779 | 9 / 10 |
| 2026-11-04 | $1.66 | $2,981,502,779 | 9 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 8 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.